Single- and multiple-dose pharmacokinetics of riluzole in white subjects

Journal of Clinical Pharmacology

Volumn 37, Issue 9, 1997, Pages 820-827

  Le Liboux, Aimé ^a   Lefebvre, Patricia ^a   Le Roux, Yvonne ^a   Truffinet, Philippe ^a   Aubeneau, Michel ^a   Kirkesseli, Stéphane ^a   Montay, Guy ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPROTECTIVE AGENT; RILUZOLE; RP 61307; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA CLEARANCE; RANDOMIZED CONTROLLED TRIAL;

EID: 0030882699     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb05630.x     Document Type: Article

References (9)

1. Couratier P, Sindou P, Esclaire F, Louvel E, Hugon J: Neuroprotective effects of riluzole in ALS CSF toxicity. Neuroreport 1994;5:1012-1014.
2. Malgouris C, Daniel M, Doble A: Neuroprotective effects of riluzole on N-methyl-d-aspartate-or veratidine-induced neurotoxicity in rat hippocampal slices. Neurosci Lett 1994;177:95-99.
3. Pratt J, Rataud J, Bardot F, Roux M, Blanchard JC, Laduron PM, Stutzmann JM: Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia. Neurosci Lett 1992;140:225-230.
4. Ringel SP, Murphy JR, Alderson MK, Bryan W, England JD, Miller RG, et al: The natural history of amyotrophic lateral sclerosis. Neurology 1993;43:1316-1322.
5. Bensimon G, Lacomblez L, Meininger V, ALS/Riluzole Study Group: A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
6. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, Amyotrophic Lateral Sclerosis/Riluzole Study Group II: Dose-ranging study of riluzole in amyotrophic lateral sclerosis. LanceṫMDBR̈ 1996;347:1425-1431.
7. Gibaldi M, Perrier D: Pharmacokinetics. 2nd Edition. New York: Marcel Dekker, 1982.
8. SIPHAR/PC. An integrated computer system for pharmacokinetic data analysis - Version 3.3, User's Manual. Creteil, France: SIMED, 1989.
9. Westlake WJ: Use of confidence intervals in analysis of comparative bioavailability trials. J Pharm Sci 1972;61:1340-1341.